US20210361581A1 - Additive for a powder material intended for compaction into shaped bodies - Google Patents
Additive for a powder material intended for compaction into shaped bodies Download PDFInfo
- Publication number
- US20210361581A1 US20210361581A1 US17/278,674 US201917278674A US2021361581A1 US 20210361581 A1 US20210361581 A1 US 20210361581A1 US 201917278674 A US201917278674 A US 201917278674A US 2021361581 A1 US2021361581 A1 US 2021361581A1
- Authority
- US
- United States
- Prior art keywords
- additive
- fatty acid
- esters
- polyglycerol fatty
- hydroxyl value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000654 additive Substances 0.000 title claims abstract description 62
- 230000000996 additive effect Effects 0.000 title claims abstract description 53
- 239000000843 powder Substances 0.000 title claims abstract description 37
- 239000000463 material Substances 0.000 title claims abstract description 35
- 238000005056 compaction Methods 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 45
- 239000000194 fatty acid Substances 0.000 claims abstract description 45
- 229930195729 fatty acid Natural products 0.000 claims abstract description 45
- 229920000223 polyglycerol Polymers 0.000 claims abstract description 44
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 20
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 19
- 238000005886 esterification reaction Methods 0.000 claims abstract description 16
- 230000032050 esterification Effects 0.000 claims abstract description 10
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims abstract description 10
- 150000002148 esters Chemical class 0.000 claims description 65
- -1 fatty acid esters Chemical class 0.000 claims description 34
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 238000007906 compression Methods 0.000 claims description 29
- 230000006835 compression Effects 0.000 claims description 25
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 14
- 229960003105 metformin Drugs 0.000 claims description 12
- 238000011835 investigation Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 238000007711 solidification Methods 0.000 claims description 11
- 230000008023 solidification Effects 0.000 claims description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 238000004458 analytical method Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000000235 small-angle X-ray scattering Methods 0.000 claims description 8
- 101100457042 Dictyostelium discoideum mgst gene Proteins 0.000 claims description 7
- 238000005299 abrasion Methods 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000005461 lubrication Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000003825 pressing Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 238000001864 heat-flux differential scanning calorimetry Methods 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000012360 testing method Methods 0.000 claims description 2
- 239000000470 constituent Substances 0.000 abstract 1
- 238000012986 modification Methods 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 238000003860 storage Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000000314 lubricant Substances 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 4
- 238000001237 Raman spectrum Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 2
- 235000021357 Behenic acid Nutrition 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 229940116226 behenic acid Drugs 0.000 description 2
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 2
- 229960003009 clopidogrel Drugs 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- BYNVYIUJKRRNNC-UHFFFAOYSA-N docosanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(O)=O BYNVYIUJKRRNNC-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- VKOBVWXKNCXXDE-UHFFFAOYSA-N ethyl stearic acid Natural products CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000004671 saturated fatty acids Chemical class 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- CTKINSOISVBQLD-UHFFFAOYSA-N Glycidol Chemical compound OCC1CO1 CTKINSOISVBQLD-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000005815 base catalysis Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000004736 wide-angle X-ray diffraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0245—Specific shapes or structures not provided for by any of the groups of A61K8/0241
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Definitions
- uniform feeding of the powder intended for compression is indispensable to smooth running of a rapid succession of compression processes.
- this can only be regularly successful when the powder is sufficiently free-flowing and does not form any agglomerates which could result in problems w the feeding and it being brought to a halt.
- polyethylene glycols abbreviated to PEGs, or glyceryl dibehenate
- PEGs polyethylene glycols
- glyceryl dibehenate polyethylene glycols
- MgSt polyethylene glycols
- MgSt are therefore in great demand because incompatibilities can occur with some powders containing pharmaceuticals, for example when they contain the antiviral acyclovir, the anticoagulant clopidogrel, the antihypertensive captopril, the antibiotics erythromycin or penicillin or the analgesic acetylsalicylic acid.
- the antidiabetic metformin which is used in its water-soluble form as metformin-HCl, is potentially incompatible with MgSt, because it can be hydrolysed and can react with the MgSt, which is a Lewis acid, in the presence of residual moisture.
- PEGs for example, are not compatible with the most widely used anti-inflammatory ibuprofen or with clopidogrel, mentioned above.
- the alternative lubricant glyceryl dibehenate it is not always possible to obtain optimal results as regards the properties of the shaped articles.
- the powders which are provided for compression into shaped articles, as disperse systems of the “solid in gas” category may consist of not only the solid particles, with particle sizes of less than 500 ⁇ m, but may also include larger components, for example pre-granulated components.
- the objective is to provide other alternatives to the aforementioned lubricants which can provide comparably good results, in order to provide alternatives in the case of problems with incompatibility or quality when using conventional lubricants.
- This objective is achieved by means of additives according to claim 1 , wherein advantageous selections of such additives are defined in the dependent claims 2 to 11 , by means of compressed material composed of powder and additive according to claim 12 , wherein advantageous compressed materials are defined in the dependent claims 13 to 17 , by means of a process according to claim 18 , in which an additive according to one of claims 1 to 11 is used and by means of shaped articles according to claim 19 , which have the advantageous properties defined in claims 20 to 23 .
- additives which, according to claim 1 , have polyglycerol fatty acid esters, abbreviated to PGFEs, as the major component, are highly suitable for influencing the cohesion and lubrication on extrinsic surfaces of a powder intended for mechanical compression into shaped articles as an alternative to MgSt when such PGFEs are used, which each can be obtained from a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids respectively containing 6 to 22 carbon atoms.
- PGFEs polyglycerol fatty acid esters
- the simplest polyglycerols which can form the starting materials for an expedient esterification are linear and branched diglycerols with the empirical formula C 6 O 5 H 14 , which can be synthesized on an industrial scale and in a known manner, for example by reacting glycerol with 2,3-epoxy-1-propanol under basic catalysis with the formation of ether bonds, or by thermal condensation under base catalysis, wherein the fraction containing mainly diglycerols can subsequently be separated.
- Diglycerols can occur in three different structurally isomeric forms, namely in the linear form, in which the ether bridge is formed between the respective first carbon atoms of the two glycerol molecules involved, in the branched form, in which the ether bridge is formed between the first carbon atom of the first and the second carbon atom of the second glycerol molecule employed, and in a nucleodendrimeric form, in which the ether bridge is formed between the respective second carbon atoms.
- the condensation of two glycerol molecules catalysed by an alkali up to approximately 80% occurs in the linear form and up to approximately 20% in the branched form, while only a very small quantity of the nucleodendrimeric form is produced.
- polyglycerols containing more than two glyceryl units may also be used.
- the polyglycerols are abbreviated to “PG” and an integer n is added as a suffix, which provides the number of polyglyceryl units, i.e. “PG n ”.
- PG n the number of polyglyceryl units
- triglycerols are written as PG 3 and have the empirical formula C 9 O 7 H 2 O.
- polyglycerols esterified with saturated unbranched fatty acids is the designation PG(n)-Cm full ester or, as appropriate, PG(n)-Cm partial ester, wherein the “n” in parentheses, in similar manner to the designation for the polyglycerols, gives the number of glyceryl units contained in the molecule and m represents the number of carbon atoms of the saturated fatty acid used for the esterification reaction.
- the “n” represents the number of glyceryl units with the empirical formula C 3 O 2 H 5 R or C 3 O 3 H 5 R 2 for marginal glyceryl units, wherein R may represent a fatty acid residue or the hydrogen atom of a free hydroxyl group.
- “PG(2)-C18 full ester” would therefore describe a polyglycerol fatty acid full ester with the empirical formula C 78 O 9 H 150 as the major component.
- the number of fatty acid residues is averaged, whereupon at the same time, the empirical formula provides the fraction with the esterification variation which is present in the majority.
- a more precise designation of the polyglycerol fatty acid partial ester is provided by additionally providing the hydroxyl value, which is a measure of the non-esterified hydroxyl group content and thus provides information regarding the degree of esterification of the partial ester. Presumably for steric reasons, the esterification reactions in this case occur preferentially from the outside to the inside. Thus, initially, the hydroxyl groups which are esterified are those which allow the fatty acid residue the highest degree of freedom.
- the first esterification reaction at a linear polyglycerol then preferentially takes place at the hydroxyl group of a first carbon atom of a marginal polyglyceryl unit, then the second esterification reaction takes place at a hydroxyl group of the third carbon atom of the marginal polyglyceryl unit at the other end.
- the hydroxyl groups at carbon atom positions immediately adjacent to positions which have already been esterified are esterified, and so on.
- fatty acids as used here should be understood to mean aliphatic monocarboxylic acids containing 6 to 22 carbon atoms, which are preferably unbranched and saturated and have an even number of carbon atoms, but they may also contain an odd number, or be branched and/or unsaturated.
- PGFEs branched monocarboxylic acids
- fatty acids which are saturated and/or unbranched are used.
- unbranched, saturated fatty acids containing 16, 18, 20 or 22 C atoms are used for the esterification, i.e. palmitic, stearic, arachidic or behenic acid.
- the PGFEs of this type which are of use are those which, when the PGFEs or individual PGFE is/are investigated using heat flux differential scanning calorimetry, during the investigation, upon heating up, have only one endothermic minimum and upon cooling down, has only one exothermic maximum, because the pressing force of 10 kN and more on the compressed material which is normally employed for compression means that increased temperatures may arise which, when unsuitable additive components are used, could lead to their polymorphic transformation and to properties of the shaped article which are difficult to control. Additional polymorphic forms would be able to be distinguished upon investigation using differential scanning calorimetry by the appearance of a local exothermic maximum upon heating the sample up, as well as a local endothermic minimum upon cooling the sample down.
- triglycerides such as glycerol tripalmitate or glycerol tristearate may have polymorphisms, i.e. respectively both a crystalline unstable a-modification as well as a metastable b′-modification or a stable b-modification may be present and transform from one into the other modification.
- the modifications differ in particular in the thickness of the lamellar, packed crystalline subunits which are also described as subcellular units.
- the PGFEs which are used to have a stable subcellular form below their solidification temperature at 40° C. and 75% relative humidity for at least 6 months, i.e. under the storage conditions for an accelerated stability test, an essentially constant thickness of the lamellar-structured crystallites evaluated by employing small angle X ray scattering, abbreviated to SAXS, and applying the Scherrer equation.
- SAXS enables conclusions to be drawn regarding the size, the shape and the internal surfaces of crystallites.
- D designates the thickness of the crystallites and K the dimensionless Scherrer constant, which enables the shape of the crystallites to be predicted and as a rule, to a good approximation, it can be taken to be 0.9.
- FWHM stands for “full width at half maximum”, i.e. the width of the peak of an intensity maximum at half the height above the background, measured in radians
- ⁇ is the Bragg angle, i.e. the angle of incidence of radiation onto the lattice plane.
- polyglycerol full esters usually exhibit a slightly higher crystallite thickness of 30 to 40 nm, indicating a higher degree of organisation, corresponding to 5 to 8 lamellae, and are also stable with unchanged modifications under the storage conditions of an accelerated stability test.
- the lamellar separation according to an evaluation of the Bragg angle using wide angle X ray scattering is substantially constant.
- WAXS wide angle X ray scattering
- This distance can be structurally associated with the a-modification in which the respective lamellar structures are disposed in a hexagonal lattice parallel to each other with molecules stacked on each other and forming planes. Other modifications cannot be identified.
- the stability of the identified a-modifications was observed both at room temperature and also at 40° C. for 6 months, also using WAXS.
- exclusively the respective polyglycerol fatty acid esters under investigation exhibited stable a-modifications.
- PGFEs from the following group are preferably selected: PG(2)-C18 full esters, PG(2)-C22 partial esters with a hydroxyl value of 15 to 100, PG(2)-C22 full esters, PG(3)-C16/C18 partial esters with a hydroxyl value of 100 to 200, PG(3)-C22 partial esters with a hydroxyl value of 100 to 200, PG(3)-C22 full esters, PG(4)-C16 partial esters with a hydroxyl value of 150 to 250, PG(4)-C16 full esters, PG(4)-C16/C18 partial esters with a hydroxyl value of 150 to 250, PG(4)-C16/C18 full esters, PG(4)-C18 partial esters with a hydroxyl value of 100 to 200, PG(4)-C22 partial esters with a hydroxyl value of 100 to 200, PG(6)-C16/C18 partial esters with a hydroxyl value of 200 to 300, PG(6)-
- hydrophobicity which can be determined by determining the contact angle.
- the contact angle ⁇ the higher is the surface tension between the PGFE and the water and the higher is the hydrophobicity of the PGFE under investigation.
- the contact angles for the proposed polyglycerol fatty acid esters also correlate with the HLB value which is often used in pharmaceutical technology, which is on a scale of 0 to 20 and provides information regarding the ratio of lipophilic to hydrophilic molecular fractions, wherein the hydrophilic fraction increases with increasing HLB value.
- the contact angle of the PGFEs used as the additive under storage conditions should undergo only moderate changes, so that the stability of the release kinetics of the pharmaceutical substance or substances produced from the finished shaped article is not compromised.
- those polyglycerol fatty acid esters which have a contact angle with water at 40° C. and also at 20° C. after 16 weeks which deviates by less than 10° from the starting value are preferably used as the major component of the additive.
- glycerol tristearate has a comparatively high contact angle deviation with water of 40° under the stated conditions and therefore deviates from the desired release kinetics stability; this can be attributed to a transformation from the a- into the b-modification during storage.
- the solidification temperature for the PGFEs used as additives is preferably below 75° C., but above 40° C.
- the solidification temperature is defined as the value for the temperature at which the maximum of the highest exothermic peak of the heat flux occurs during analysis of a sample using differential scanning calorimetry.
- PGFEs are always mixtures of different molecules, in particular in the case of partial esters. It is, however, also possible for a suitable additive in accordance with claim 1 to be provided after synthesis by mixing those PGFEs which can respectively be obtained by esterification reactions which are different because different reaction partners or different reaction conditions are employed.
- the size of the particles of additive has an influence on the total surface area of the additive, and therefore on the properties of the composition formed by the powder for compression and the additive.
- the particle size of the additive it has been shown to be advantageous for the particle size of the additive to be 1 to 300 ⁇ m, preferably 5 ⁇ m to 15 ⁇ m.
- the proportion of additives in the composition also has an influence on their behaviour when mechanically compressing into shaped articles and should advantageously not exceed 5% by weight; preferably, it is only 0.05% to 0.5% by weight. Too much additive is associated with increased hydrophobicity of the composition and could have negative effects on the wettability of the prepared shaped article; its dissolution behaviour could then be slowed down in an undesirable manner.
- the compressed material formed from the powder provided for mechanical compression into a shaped article and the additive comprises at least one pharmaceutical substance, such as metformin-HCl, for example.
- pharmaceutical substance should be understood to mean both directly pharmacologically effective substances and also substances which are only effective after in vivo transformation into an active form.
- the powder preferably contains microcrystalline cellulose as a filler; the proportion of this in the compressed material enables the volume of the shaped article to be controlled.
- the compressed material formed from the additive and the powder has only 0.05% to 0.5% by weight of additive and 99.5% to 99.95% by weight of powder, wherein the additive consists of a mixture of respectively 50% by weight of PG(3)-C22 full ester and PG(3)-C22 partial ester with a hydroxyl value of 100-200 or entirely of PG(3)-C22 partial ester with the same hydroxyl value.
- the compressed material may also contain a proportion of 15% by weight of metformin-HCl, for example, and a proportion of 84.5% to 84.95% by weight of microcrystalline cellulose.
- the additive is preferably mixed with the powder. This is because correct feeding to the compression site in a shaped article compressing machine, as a rule into the die of a tablet press, is also critically dependent on the flow properties of the powder which are influenced by the additive in a manner such that the feed of the compressed material occurs uniformly and without stoppages.
- the shaped article should have the same composition as the compressed material and during compression and the supply of energy associated therewith, should not undergo any chemical changes.
- the force required for ejecting the shaped article is no more than 150% of the ejection force which is required under otherwise identical conditions for a test shaped article in which at least 40% by weight of the additive has been replaced by MgSt and the remainder optionally by the filler employed, preferably microcrystalline cellulose.
- values for 20 shaped articles are averaged each time.
- the upper punch is forced onto the compressed material lying on the lower punch, while in this step, the lower punch is moved in the direction of the upper punch.
- the specific maximum pressure at the upper punch for the respective compression process is thus transferred to a certain extent onto the lower punch via the compressed material.
- an amount of additive is added to the powder intended for compression which is such that for a punch diameter of 8 mm and an injection of 285 mg of compressed material, at the time of a maximum pressure of 10 kN at the upper punch, the maximum pressure at the lower punch is 92% to 98% of the maximum pressure of the upper punch.
- the quantity of additive which is added to the powder intended for compression is measured correctly. This can be established on the basis of the resulting properties of the shaped article, which preferably exhibit no breakage under a linear effective force of up to 100 N, preferably up to 150 N and particularly preferably up to 200 N. In order to determine the breaking strength, the linear effective force is respectively applied to 10 shaped articles and the average value is determined.
- the abrasion is determined: in accordance with the European Pharmacopoeia, issue 8.0, a number of shaped articles with a total weight of as close to 6.5 g as possible are placed in a rotating drum after they have been carefully freed from any abraded material or dust already present. The drum is then rotated 100 times at a speed of 25 revolutions per minute. Next, the shaped articles are carefully freed from abraded material and dust once again, weighed and the average weight which is determined is compared with the starting weight. It has been shown to be advantageous for the weight loss by dust using this procedure to be no more than 0.02% to 0.25% by weight.
- the shaped articles in accordance with the invention should advantageously have a disintegration time of 2 to 4 minutes.
- 6 shaped articles, each placed in separate baskets are placed in 100 mL of purified water, aqua purificata, which has been heated to a temperature of 37° C. ( ⁇ 2° C.).
- the baskets are then moved 53 to 57 mm back and forth, 29 to 32 times per minute, and at predetermined times the disintegration status of the shaped articles and baskets removed from the water is assessed in accordance with the European Pharmacopoeia, issue 8.0.
- PG(3)-C22 partial esters with a hydroxyl value of 138 were firstly micronized using supercritical fluid technology, abbreviated to “SCFT”, using carbon dioxide as the fluid; the median particle size for all of the particles was 13.15 ⁇ m ( ⁇ 0.05 ⁇ m). A proportion of these particles was used as an additive.
- the pharmaceutical substance was metformin-HCl; the filler was microcrystalline cellulose, known by the trade name Avicel PH102. Prior to mixing, the metformin-HCl was passed through a sieve with a pore size of 200 ⁇ m.
- the powder was therefore a mixture of metformin-HCl and microcrystalline cellulose
- the additive was PG(3)-C22 partial ester-[138], wherein the number in square brackets gives the hydroxyl value here.
- the compressed material was obtained by mixing these components in a Turbula TC2 mixer from Willy A Bachofen Maschinenfabrik (CH) at 75 revolutions per minute for 10 minutes; the compressed material consisted of 15% by weight of metformin-HCl, 84.75% by weight of microcrystalline cellulose and 0.25% by weight of PG(3)-C22 partial ester-[138].
- the compressed material was compressed into flat tablets in a Stylcam 200R compacting simulator from Medelpharm (FR) using punches and dies from Natoli (USA) with a diameter of 8 mm.
- the subsequent investigations of the prepared tablets in accordance with European Pharmacopoeia issue 8.0 provided a disintegration time of only 2 minutes, an abrasion of 0.12%.
- the breaking strength of the tablets was strong enough to withstand a linear effective force of up to 140 N; the ejection force to remove the tablets from the die was only 120 N.
- the composition of the compressed material was varied; 84.9% by weight of microcrystalline cellulose, 15% by weight of metformin-HCl and 0.1% by weight of a blend of equal parts of PG(3)-C22 full ester and PG(3)-C22 partial ester-[138] were compressed.
- the disintegration time was 4 minutes
- the abrasion was only 0.02%
- the breaking strength of the tablets was strong enough to withstand a linear effective force of up to 200 N and the ejection force required was 175 N.
- the partial ester PG(4)-C18 had the quantitative main structure shown in FIG. 1 , when investigated using gas chromatography linked with mass spectroscopy (GC-MS).
- FIG. 2 shows the results of the investigation of PG(4)-C18 using differential scanning calorimetry, wherein the temperature values are on the X axis of the diagram and the heat flux in mW/g is on the Y axis.
- the left hand diagram in FIG. 2 shows two almost coincident curves for two measurements of the partial ester PG(4)-C18, which each exhibit precisely one endothermic minimum which can be assigned to the energy-consuming transition from the solid to the liquid phase upon melting of the partial ester.
- the right hand diagram for the partial ester PG(4)-C18 in FIG. 2 shows precisely one exothermic maximum which can be assigned to the energy-releasing transition from the liquid to the solid phase upon solidification of the partial ester.
- the measurements were carried out using a DSC 204 F1 Phoenix from Nietzsch Gerstebau GmbH, 95100 Selb, Germany.
- a sample of 3-4 mg was weighed into an aluminium crucible and the heat flux was continuously recorded at a heating rate of 5K per minute.
- a second run was carried out using the same heating rate.
- FIG. 3 shows, as a contrast to the desired behaviour of the polyglycerol fatty acid ester, the typical behaviour of a polymorphic triacyl glycerol during an investigation using differential scanning calorimetry and upon heating up.
- two local endothermic minima with an intermediate exothermic maximum can be seen, wherein the first endothermic minimum on the left hand side is due to melting of the unstable a-modification followed by the exothermic maximum upon crystallization to form the more stable b-modification, which in turn melts as the temperature rises further, as can be seen by the second local endothermic minimum on the right hand side.
- FIG. 4 shows the PG(4)-C18 partial ester investigated using differential scanning calorimetry upon heating up, after storage for 6 months at room temperature.
- FIG. 5 shows the PG(4)-C18 partial ester investigated using differential scanning calorimetry, upon heating up after storage for 6 months at 40° C. In both cases, as before, there is no exothermic maximum which could indicate crystallization into a more stable modification.
- FIG. 6 shows the results of the WAXS analysis for different polyglycerol fatty acid esters including PG(4)-C18 partial ester (labelled) below their solidification temperature, which all exhibit an intensity maximum at a 20 of 21.4°.
- the Bragg angle corresponds to a separation of the lattice planes of 415 ⁇ m, which is typical for the lamellar packing of the a-modification.
- the maximum intensity was stable both after storage for 6 months at room temperature, as can be seen in FIG. 7 , and also after storage for 6 months at 40° C., as can be seen in FIG. 8 .
- FIG. 9 shows the results of the SAXS analysis for various polyglycerol fatty acid esters.
- PG(4)-C18 partial ester For PG(4)-C18 partial ester, a lamellar separation of 65.2 Angstroms could be derived.
- the thickness of the crystallites, calculated from the Scherrer equation, was 12.5 nm with a Scherrer constant of 0.9, a wavelength of 1.542 Angstroms, a FWHM value of 0.0111 and a Bragg angle 9 of 0.047 (radians).
- the values for the SAXS analysis of PG(4)-C18 partial ester remained the same even after storage for six months, both at room temperature and also at 40° C. (not shown).
- the analysis from the differential scanning calorimetry also enabled predictions to be made about the solidification temperature of the PG(4)-C18 partial ester.
- the peak of the exothermic maximum upon cooling the sample down was between 53.4° C. and 57.0° C. with the maximum at 55.2° C., which marks the solidification temperature.
- FIG. 10 shows a diagram illustrating the measurement of the contact angle (see para [0020]).
- the contact angle is approximately 84°, which correlates to a HLB value of approximately 5.2.
- FIG. 12 shows the variation in contact angle for PG(4)-C18 partial esters, see central graph, against the start measurement (left hand column), after 16 weeks at room temperature (central column) and after 16 weeks at 40° C. (right hand column).
- the contact angle varied by no more than 10°, and so the hydrophobicity can be described as stable compared with monoglycerol fatty acid esters such as tristearyl glycerol, for example.
- monoglycerol fatty acid esters such as tristearyl glycerol, for example.
- PG3-C16/C18 partial ester also shown in FIG. 12 , left hand graph, and PG6-C18 partial esters, right hand graph.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Geometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
- When manufacturing pharmaceuticals, and also when manufacturing food supplements, there is frequently a need to compress powdered components into shaped articles which are usually cylindrical in shape and are largely used as tablets. In other industrial fields as well, shaped articles are produced from powders; an example is in the detergent industry. Requirements in the pharmaceutical industry are particularly stringent because here, a reproducible release of the pharmaceutical material has to be guaranteed, along with a sufficient breaking strength and low abrasion of the shaped article. Moreover, they are produced in large numbers and the ability to compress the powder to be compressed uniformly on rapid rotary presses is demanded, wherein the pressing tools must neither be damaged by superfluous shear forces, nor can dissolving the shaped article at the point of use be compromised. In addition, uniform feeding of the powder intended for compression is indispensable to smooth running of a rapid succession of compression processes. However, this can only be regularly successful when the powder is sufficiently free-flowing and does not form any agglomerates which could result in problems w the feeding and it being brought to a halt.
- In order to obtain a rapid, effective and uniform mechanical compression process with good results and simultaneously with optimized machine downtimes and maintenance cycles for worn parts, it has become standard practice to add what are known as lubricants as an additive to powders intended for compression, which lubricants reduce both the mutual cohesion of the powder components and also the adhesion of the powder to extrinsic surfaces without, however, the properties of the shaped article formed from the powder as regards wettability and consistency being affected too greatly. The use of magnesium distearate, C26H70MgO4, abbreviated to MgSt, has been shown to be particularly advantageous. As an alternative, for example, polyethylene glycols, abbreviated to PEGs, or glyceryl dibehenate, may also be used, wherein the latter is used as a mixture of mono-, di- and tri-esters of behenic acid which contains only the diesters as the main component. Alternatives to MgSt are therefore in great demand because incompatibilities can occur with some powders containing pharmaceuticals, for example when they contain the antiviral acyclovir, the anticoagulant clopidogrel, the antihypertensive captopril, the antibiotics erythromycin or penicillin or the analgesic acetylsalicylic acid. Even the antidiabetic metformin, which is used in its water-soluble form as metformin-HCl, is potentially incompatible with MgSt, because it can be hydrolysed and can react with the MgSt, which is a Lewis acid, in the presence of residual moisture. PEGs, for example, are not compatible with the most widely used anti-inflammatory ibuprofen or with clopidogrel, mentioned above. Regarding the alternative lubricant glyceryl dibehenate, it is not always possible to obtain optimal results as regards the properties of the shaped articles. The powders which are provided for compression into shaped articles, as disperse systems of the “solid in gas” category, may consist of not only the solid particles, with particle sizes of less than 500 μm, but may also include larger components, for example pre-granulated components.
- Thus, the objective is to provide other alternatives to the aforementioned lubricants which can provide comparably good results, in order to provide alternatives in the case of problems with incompatibility or quality when using conventional lubricants. This objective is achieved by means of additives according to
claim 1, wherein advantageous selections of such additives are defined in the dependent claims 2 to 11, by means of compressed material composed of powder and additive according to claim 12, wherein advantageous compressed materials are defined in the dependent claims 13 to 17, by means of a process according toclaim 18, in which an additive according to one ofclaims 1 to 11 is used and by means of shaped articles according to claim 19, which have the advantageous properties defined inclaims 20 to 23. - Surprisingly, it has now been shown for the first time that additives which, according to
claim 1, have polyglycerol fatty acid esters, abbreviated to PGFEs, as the major component, are highly suitable for influencing the cohesion and lubrication on extrinsic surfaces of a powder intended for mechanical compression into shaped articles as an alternative to MgSt when such PGFEs are used, which each can be obtained from a complete or partial esterification of a linear or branched polyglycerol containing two to eight glyceryl units with one or more fatty acids respectively containing 6 to 22 carbon atoms. - The simplest polyglycerols which can form the starting materials for an expedient esterification are linear and branched diglycerols with the empirical formula C6O5H14, which can be synthesized on an industrial scale and in a known manner, for example by reacting glycerol with 2,3-epoxy-1-propanol under basic catalysis with the formation of ether bonds, or by thermal condensation under base catalysis, wherein the fraction containing mainly diglycerols can subsequently be separated.
- Diglycerols can occur in three different structurally isomeric forms, namely in the linear form, in which the ether bridge is formed between the respective first carbon atoms of the two glycerol molecules involved, in the branched form, in which the ether bridge is formed between the first carbon atom of the first and the second carbon atom of the second glycerol molecule employed, and in a nucleodendrimeric form, in which the ether bridge is formed between the respective second carbon atoms. In the case of the condensation of two glycerol molecules catalysed by an alkali, up to approximately 80% occurs in the linear form and up to approximately 20% in the branched form, while only a very small quantity of the nucleodendrimeric form is produced.
- In the case of esterification with fatty acids, polyglycerols containing more than two glyceryl units may also be used. In general, the polyglycerols are abbreviated to “PG” and an integer n is added as a suffix, which provides the number of polyglyceryl units, i.e. “PGn”. As an example, triglycerols are written as PG3 and have the empirical formula C9O7H2O. Complete esterification with a fatty acid, for example with stearic acid, should now take place at all of the free hydroxyl groups of the PGn molecule. In the case of a linear PG3, then this would take place at the first and second carbon atoms of the first glyceryl unit, at the second carbon atom of the second glyceryl unit and at the second and third carbon atoms of the third glyceryl unit. The empirical formula for this example is therefore given as C9O7H15R5, wherein each R represents a fatty acid residue, in the selected example with the empirical formula C18OH35.
- However, the established abbreviation for polyglycerols esterified with saturated unbranched fatty acids is the designation PG(n)-Cm full ester or, as appropriate, PG(n)-Cm partial ester, wherein the “n” in parentheses, in similar manner to the designation for the polyglycerols, gives the number of glyceryl units contained in the molecule and m represents the number of carbon atoms of the saturated fatty acid used for the esterification reaction. Thus, the “n” represents the number of glyceryl units with the empirical formula C3O2H5R or C3O3H5R2 for marginal glyceryl units, wherein R may represent a fatty acid residue or the hydrogen atom of a free hydroxyl group. “PG(2)-C18 full ester” would therefore describe a polyglycerol fatty acid full ester with the empirical formula C78O9H150 as the major component. In the case of the PG partial ester, the number of fatty acid residues is averaged, whereupon at the same time, the empirical formula provides the fraction with the esterification variation which is present in the majority. A more precise designation of the polyglycerol fatty acid partial ester is provided by additionally providing the hydroxyl value, which is a measure of the non-esterified hydroxyl group content and thus provides information regarding the degree of esterification of the partial ester. Presumably for steric reasons, the esterification reactions in this case occur preferentially from the outside to the inside. Thus, initially, the hydroxyl groups which are esterified are those which allow the fatty acid residue the highest degree of freedom. The first esterification reaction at a linear polyglycerol then preferentially takes place at the hydroxyl group of a first carbon atom of a marginal polyglyceryl unit, then the second esterification reaction takes place at a hydroxyl group of the third carbon atom of the marginal polyglyceryl unit at the other end. Next, the hydroxyl groups at carbon atom positions immediately adjacent to positions which have already been esterified are esterified, and so on.
- The term “fatty acids” as used here should be understood to mean aliphatic monocarboxylic acids containing 6 to 22 carbon atoms, which are preferably unbranched and saturated and have an even number of carbon atoms, but they may also contain an odd number, or be branched and/or unsaturated. Preferably, for the esterification of the PGFEs used as the major component of the additive, fatty acids which are saturated and/or unbranched are used. More advantageously, unbranched, saturated fatty acids containing 16, 18, 20 or 22 C atoms are used for the esterification, i.e. palmitic, stearic, arachidic or behenic acid.
- Advantageously, the PGFEs of this type which are of use are those which, when the PGFEs or individual PGFE is/are investigated using heat flux differential scanning calorimetry, during the investigation, upon heating up, have only one endothermic minimum and upon cooling down, has only one exothermic maximum, because the pressing force of 10 kN and more on the compressed material which is normally employed for compression means that increased temperatures may arise which, when unsuitable additive components are used, could lead to their polymorphic transformation and to properties of the shaped article which are difficult to control. Additional polymorphic forms would be able to be distinguished upon investigation using differential scanning calorimetry by the appearance of a local exothermic maximum upon heating the sample up, as well as a local endothermic minimum upon cooling the sample down. The “blooming” that occurs after some time in storage in which the polymorphism of a component causes a substantial increase in volume which is macroscopically visible, can be avoided by using additives which exhibit no polymorphism. In particular, triglycerides such as glycerol tripalmitate or glycerol tristearate may have polymorphisms, i.e. respectively both a crystalline unstable a-modification as well as a metastable b′-modification or a stable b-modification may be present and transform from one into the other modification. In this regard, the modifications differ in particular in the thickness of the lamellar, packed crystalline subunits which are also described as subcellular units. As an example, for the a-modification of glycerol tristearate, under specific conditions, stacking of an average of 6 lamellar structures per subcellular unit could be detected and after complete transformation into the b-modification, stacking of an average of 10.5 lamellar structures per subcellular unit and an increase in the crystal thickness of approximately 67% was observed. Because in this case, the computed expected increase of 75% is not obtained, this is presumed to be due to the fact that the individual lamellae of the b-modification have a denser lamellar packing because of the inclined position compared with the a-modification (see D G Lopes, K Becker, M Stehr, D Lochmann et al., in the Journal of Pharmaceutical Sciences 104: 4257-4265, 2015).
- Because the additives remain in the final product, it is also advantageous for the PGFEs which are used to have a stable subcellular form below their solidification temperature at 40° C. and 75% relative humidity for at least 6 months, i.e. under the storage conditions for an accelerated stability test, an essentially constant thickness of the lamellar-structured crystallites evaluated by employing small angle X ray scattering, abbreviated to SAXS, and applying the Scherrer equation. SAXS enables conclusions to be drawn regarding the size, the shape and the internal surfaces of crystallites. The thickness of the respective crystallites can be calculated here using the Scherrer equation, which is D=Kλ/FWHM cos (θ). Here, D designates the thickness of the crystallites and K the dimensionless Scherrer constant, which enables the shape of the crystallites to be predicted and as a rule, to a good approximation, it can be taken to be 0.9. FWHM stands for “full width at half maximum”, i.e. the width of the peak of an intensity maximum at half the height above the background, measured in radians, and θ is the Bragg angle, i.e. the angle of incidence of radiation onto the lattice plane. While a sample of glycerol tripalmitate stabilized with 10% polysorbate 65 has a crystallite thickness of 31 nm after storage for six months at room temperature, corresponding to seven lamellae, and the crystallite thickness after storage for six months at 40° C. is 52 nm, corresponding to 12 lamellae, is almost double, the aforementioned polyglycerol fatty acid esters usually exhibit crystallite thicknesses of 20 to 30 nm, corresponding to 2 to 4 lamellae, and are stable after six months storage at 40° C., with the modifications unchanged. In contrast, polyglycerol full esters usually exhibit a slightly higher crystallite thickness of 30 to 40 nm, indicating a higher degree of organisation, corresponding to 5 to 8 lamellae, and are also stable with unchanged modifications under the storage conditions of an accelerated stability test.
- It is also advantageous if, when the PGFEs are used under the stated conditions, the lamellar separation according to an evaluation of the Bragg angle using wide angle X ray scattering, abbreviated to “WAXS”, is substantially constant. Individual investigations of the proposed polyglycerol fatty acid esters below their respective solidification temperature using WAXS exhibit one maximum intensity for all polyglycerol fatty acid esters which have been investigated, which means that a respective deflection angle of 21.4°, corresponding to approximately 20, i.e. double the Bragg angle, can be deduced, which gives a separation of the lattice planes of 415 μm, which correlates here with the lamellar packing density of the molecules under investigation. This distance can be structurally associated with the a-modification in which the respective lamellar structures are disposed in a hexagonal lattice parallel to each other with molecules stacked on each other and forming planes. Other modifications cannot be identified. The stability of the identified a-modifications was observed both at room temperature and also at 40° C. for 6 months, also using WAXS. Here again, surprisingly, exclusively the respective polyglycerol fatty acid esters under investigation exhibited stable a-modifications.
- For the preparation of the additives, PGFEs from the following group are preferably selected: PG(2)-C18 full esters, PG(2)-C22 partial esters with a hydroxyl value of 15 to 100, PG(2)-C22 full esters, PG(3)-C16/C18 partial esters with a hydroxyl value of 100 to 200, PG(3)-C22 partial esters with a hydroxyl value of 100 to 200, PG(3)-C22 full esters, PG(4)-C16 partial esters with a hydroxyl value of 150 to 250, PG(4)-C16 full esters, PG(4)-C16/C18 partial esters with a hydroxyl value of 150 to 250, PG(4)-C16/C18 full esters, PG(4)-C18 partial esters with a hydroxyl value of 100 to 200, PG(4)-C22 partial esters with a hydroxyl value of 100 to 200, PG(6)-C16/C18 partial esters with a hydroxyl value of 200 to 300, PG(6)-C16/C18 full esters, PG(6)-C18 partial esters with a hydroxyl value of 100 to 200, wherein in the polyglycerol fatty acid esters containing two fatty acid residues which are different because of the number of their carbon atoms, those with a lower number are present in an amount of 35% to 45%, those with a corresponding, complementary higher number are present in an amount of 55% to 65% and the specified full esters preferably have a hydroxyl value of less than 5.
- An advantageous property of the PGFEs for an additive in accordance with
claim 1 which should be considered is the hydrophobicity, which can be determined by determining the contact angle. The determination of the hydrophobicity is carried out by determining the contact angle between the PGFE in the solid physical state and a droplet of purified water. According to Young's equation, cos θ=(γSV−γSL)/γLV, wherein γSL is the interfacial tension between the PGFE and water, γLV is the interfacial tension of the water droplet and γSV is the surface tension between the PGFE and the surrounding air. θ is the contact angle. Thus, the larger the contact angle θ, the higher is the surface tension between the PGFE and the water and the higher is the hydrophobicity of the PGFE under investigation. The contact angles for the proposed polyglycerol fatty acid esters also correlate with the HLB value which is often used in pharmaceutical technology, which is on a scale of 0 to 20 and provides information regarding the ratio of lipophilic to hydrophilic molecular fractions, wherein the hydrophilic fraction increases with increasing HLB value. For the compression of a powder comprising one or more pharmaceutical substances, the contact angle of the PGFEs used as the additive under storage conditions should undergo only moderate changes, so that the stability of the release kinetics of the pharmaceutical substance or substances produced from the finished shaped article is not compromised. Thus, preferably, those polyglycerol fatty acid esters which have a contact angle with water at 40° C. and also at 20° C. after 16 weeks which deviates by less than 10° from the starting value are preferably used as the major component of the additive. As an example, glycerol tristearate has a comparatively high contact angle deviation with water of 40° under the stated conditions and therefore deviates from the desired release kinetics stability; this can be attributed to a transformation from the a- into the b-modification during storage. The solidification temperature for the PGFEs used as additives is preferably below 75° C., but above 40° C. Here, the solidification temperature is defined as the value for the temperature at which the maximum of the highest exothermic peak of the heat flux occurs during analysis of a sample using differential scanning calorimetry. - Because of the conditions for their synthesis, PGFEs are always mixtures of different molecules, in particular in the case of partial esters. It is, however, also possible for a suitable additive in accordance with
claim 1 to be provided after synthesis by mixing those PGFEs which can respectively be obtained by esterification reactions which are different because different reaction partners or different reaction conditions are employed. - The size of the particles of additive has an influence on the total surface area of the additive, and therefore on the properties of the composition formed by the powder for compression and the additive. In principle, it has been shown to be advantageous for the particle size of the additive to be 1 to 300 μm, preferably 5 μm to 15 μm. Correspondingly, the proportion of additives in the composition also has an influence on their behaviour when mechanically compressing into shaped articles and should advantageously not exceed 5% by weight; preferably, it is only 0.05% to 0.5% by weight. Too much additive is associated with increased hydrophobicity of the composition and could have negative effects on the wettability of the prepared shaped article; its dissolution behaviour could then be slowed down in an undesirable manner.
- For applications in the pharmaceutical industry, the compressed material formed from the powder provided for mechanical compression into a shaped article and the additive comprises at least one pharmaceutical substance, such as metformin-HCl, for example. The term “pharmaceutical substance” should be understood to mean both directly pharmacologically effective substances and also substances which are only effective after in vivo transformation into an active form. In addition, the powder preferably contains microcrystalline cellulose as a filler; the proportion of this in the compressed material enables the volume of the shaped article to be controlled.
- It has been shown to be advantageous for the compressed material formed from the additive and the powder to have only 0.05% to 0.5% by weight of additive and 99.5% to 99.95% by weight of powder, wherein the additive consists of a mixture of respectively 50% by weight of PG(3)-C22 full ester and PG(3)-C22 partial ester with a hydroxyl value of 100-200 or entirely of PG(3)-C22 partial ester with the same hydroxyl value. In addition to the additive, the compressed material may also contain a proportion of 15% by weight of metformin-HCl, for example, and a proportion of 84.5% to 84.95% by weight of microcrystalline cellulose.
- For an optimized action of the additive as regards the influence on the cohesion and the lubrication on extrinsic surfaces for a powder intended for mechanical compression into shaped articles, prior to compression, preferably, before being fed to the compression site, the additive is preferably mixed with the powder. This is because correct feeding to the compression site in a shaped article compressing machine, as a rule into the die of a tablet press, is also critically dependent on the flow properties of the powder which are influenced by the additive in a manner such that the feed of the compressed material occurs uniformly and without stoppages.
- Furthermore, removal of the prepared shaped article from the respective mould is a process which can only be carried out without problems when the composition of the shaped article guarantees a sufficient lubrication on extrinsic surfaces. Thus, the shaped article should have the same composition as the compressed material and during compression and the supply of energy associated therewith, should not undergo any chemical changes. This is of advantage if the force required for ejecting the shaped article is no more than 150% of the ejection force which is required under otherwise identical conditions for a test shaped article in which at least 40% by weight of the additive has been replaced by MgSt and the remainder optionally by the filler employed, preferably microcrystalline cellulose. In order to determine the ejection force, values for 20 shaped articles are averaged each time.
- During compression of the compressed material composed of additive and powder by means of a rotary press, in the final step of the compression process, the upper punch is forced onto the compressed material lying on the lower punch, while in this step, the lower punch is moved in the direction of the upper punch. The specific maximum pressure at the upper punch for the respective compression process is thus transferred to a certain extent onto the lower punch via the compressed material. Advantageously, an amount of additive is added to the powder intended for compression which is such that for a punch diameter of 8 mm and an injection of 285 mg of compressed material, at the time of a maximum pressure of 10 kN at the upper punch, the maximum pressure at the lower punch is 92% to 98% of the maximum pressure of the upper punch.
- If a quantity of additive is added to the powder intended for compression into shaped articles which is too small, then there is a risk that the desired effect, namely a reduced cohesion of the powder particles with respect to each other and a reduced adhesion to extrinsic surfaces, is not sufficient, with the consequence that the compressed material could stop flowing even when it is being fed to the compression site, the pressing tools could be blocked by sticking particles or the required pressure could still be so high that the shaped articles obtained dissolve too slowly under physiological conditions, and so the substance would not be taken up quickly enough and the pharmaceutical effect would not occur. On the other hand, too large a quantity of additive could result in the shaped articles obtained by compression not having the hardness required for pharmaceuticals, and so might break up, which is undesirable, or abrade too much, which would lead to unacceptable variations in the targeted uniform active ingredient content of the shaped article. Thus, advantageously and desirably, the quantity of additive which is added to the powder intended for compression is measured correctly. This can be established on the basis of the resulting properties of the shaped article, which preferably exhibit no breakage under a linear effective force of up to 100 N, preferably up to 150 N and particularly preferably up to 200 N. In order to determine the breaking strength, the linear effective force is respectively applied to 10 shaped articles and the average value is determined. Furthermore, the abrasion is determined: in accordance with the European Pharmacopoeia, issue 8.0, a number of shaped articles with a total weight of as close to 6.5 g as possible are placed in a rotating drum after they have been carefully freed from any abraded material or dust already present. The drum is then rotated 100 times at a speed of 25 revolutions per minute. Next, the shaped articles are carefully freed from abraded material and dust once again, weighed and the average weight which is determined is compared with the starting weight. It has been shown to be advantageous for the weight loss by dust using this procedure to be no more than 0.02% to 0.25% by weight.
- Finally, according to the European Pharmacopoeia, issue 8.0, the shaped articles in accordance with the invention should advantageously have a disintegration time of 2 to 4 minutes. In this regard, in each case 6 shaped articles, each placed in separate baskets, are placed in 100 mL of purified water, aqua purificata, which has been heated to a temperature of 37° C. (±2° C.). The baskets are then moved 53 to 57 mm back and forth, 29 to 32 times per minute, and at predetermined times the disintegration status of the shaped articles and baskets removed from the water is assessed in accordance with the European Pharmacopoeia, issue 8.0.
- The invention will now be illustrated with the aid of an example of the additive in accordance with the invention, the compressed material in accordance with the invention, the process in accordance with the invention and the shaped articles in accordance with the invention.
- PG(3)-C22 partial esters with a hydroxyl value of 138 were firstly micronized using supercritical fluid technology, abbreviated to “SCFT”, using carbon dioxide as the fluid; the median particle size for all of the particles was 13.15 μm (±0.05 μm). A proportion of these particles was used as an additive. The pharmaceutical substance was metformin-HCl; the filler was microcrystalline cellulose, known by the trade name Avicel PH102. Prior to mixing, the metformin-HCl was passed through a sieve with a pore size of 200 μm. In this example, the powder was therefore a mixture of metformin-HCl and microcrystalline cellulose, the additive was PG(3)-C22 partial ester-[138], wherein the number in square brackets gives the hydroxyl value here. The compressed material was obtained by mixing these components in a Turbula TC2 mixer from Willy A Bachofen Maschinenfabrik (CH) at 75 revolutions per minute for 10 minutes; the compressed material consisted of 15% by weight of metformin-HCl, 84.75% by weight of microcrystalline cellulose and 0.25% by weight of PG(3)-C22 partial ester-[138]. The compressed material was compressed into flat tablets in a Stylcam 200R compacting simulator from Medelpharm (FR) using punches and dies from Natoli (USA) with a diameter of 8 mm. The subsequent investigations of the prepared tablets in accordance with European Pharmacopoeia issue 8.0 provided a disintegration time of only 2 minutes, an abrasion of 0.12%. The breaking strength of the tablets was strong enough to withstand a linear effective force of up to 140 N; the ejection force to remove the tablets from the die was only 120 N.
- In a second example, the composition of the compressed material was varied; 84.9% by weight of microcrystalline cellulose, 15% by weight of metformin-HCl and 0.1% by weight of a blend of equal parts of PG(3)-C22 full ester and PG(3)-C22 partial ester-[138] were compressed. For this example, the disintegration time was 4 minutes, the abrasion was only 0.02%, the breaking strength of the tablets was strong enough to withstand a linear effective force of up to 200 N and the ejection force required was 175 N.
- The investigation of the RAMAN spectra of a modified compressed material which consisted of 95% metformin-HCl and 5% additive, or alternatively 50% metformin-HCl and 50% additive, compared with the RAMAN spectra of the individual components and compared with the RAMAN spectra of the tablets prepared from it, indicated that there were no interactions or incompatibilities between the additive and the pharmaceutical substance, even after storage of the tablets for one month at 40° C. The variation in the composition of the compressed material compared with the preceding example was made in order to provoke any opposing influences of the components before, during and after compression by leaving out the filler and to make them more noticeable.
- The properties of some PGFEs will now be illustrated by way of example and with the aid of the figures.
- The partial ester PG(4)-C18 had the quantitative main structure shown in
FIG. 1 , when investigated using gas chromatography linked with mass spectroscopy (GC-MS). -
FIG. 2 shows the results of the investigation of PG(4)-C18 using differential scanning calorimetry, wherein the temperature values are on the X axis of the diagram and the heat flux in mW/g is on the Y axis. The left hand diagram inFIG. 2 shows two almost coincident curves for two measurements of the partial ester PG(4)-C18, which each exhibit precisely one endothermic minimum which can be assigned to the energy-consuming transition from the solid to the liquid phase upon melting of the partial ester. The right hand diagram for the partial ester PG(4)-C18 inFIG. 2 shows precisely one exothermic maximum which can be assigned to the energy-releasing transition from the liquid to the solid phase upon solidification of the partial ester. The measurements were carried out using a DSC 204 F1 Phoenix from Nietzsch Gerstebau GmbH, 95100 Selb, Germany. In this regard, a sample of 3-4 mg was weighed into an aluminium crucible and the heat flux was continuously recorded at a heating rate of 5K per minute. A second run was carried out using the same heating rate. -
FIG. 3 shows, as a contrast to the desired behaviour of the polyglycerol fatty acid ester, the typical behaviour of a polymorphic triacyl glycerol during an investigation using differential scanning calorimetry and upon heating up. Here, two local endothermic minima with an intermediate exothermic maximum can be seen, wherein the first endothermic minimum on the left hand side is due to melting of the unstable a-modification followed by the exothermic maximum upon crystallization to form the more stable b-modification, which in turn melts as the temperature rises further, as can be seen by the second local endothermic minimum on the right hand side. -
FIG. 4 shows the PG(4)-C18 partial ester investigated using differential scanning calorimetry upon heating up, after storage for 6 months at room temperature.FIG. 5 shows the PG(4)-C18 partial ester investigated using differential scanning calorimetry, upon heating up after storage for 6 months at 40° C. In both cases, as before, there is no exothermic maximum which could indicate crystallization into a more stable modification. - For the WAXS and the SAXS analyses, a spot focusing camera system, S3-MICRO, formerly Hecus X ray Systems Gesmbh, 8020 Graz, Austria, now Bruker AXS GmbH, 76187 Karlsruhe, Germany, was equipped with two linear position-sensitive detectors with a resolution of 3.3-4.9 Angstroms (WAXS) and 10-1500 Angstroms (SAXS). The samples were introduced into a glass capillary with a diameter of approximately 2 mm, which was then sealed with wax and placed in the rotary capillary unit. The individual measurements were made at room temperature by exposure to a beam of X rays at a wavelength of 1.542 Angstroms for 1300 sec.
-
FIG. 6 shows the results of the WAXS analysis for different polyglycerol fatty acid esters including PG(4)-C18 partial ester (labelled) below their solidification temperature, which all exhibit an intensity maximum at a 20 of 21.4°. The Bragg angle corresponds to a separation of the lattice planes of 415 μm, which is typical for the lamellar packing of the a-modification. The maximum intensity was stable both after storage for 6 months at room temperature, as can be seen inFIG. 7 , and also after storage for 6 months at 40° C., as can be seen inFIG. 8 . -
FIG. 9 shows the results of the SAXS analysis for various polyglycerol fatty acid esters. For PG(4)-C18 partial ester, a lamellar separation of 65.2 Angstroms could be derived. The thickness of the crystallites, calculated from the Scherrer equation, was 12.5 nm with a Scherrer constant of 0.9, a wavelength of 1.542 Angstroms, a FWHM value of 0.0111 and a Bragg angle 9 of 0.047 (radians). The values for the SAXS analysis of PG(4)-C18 partial ester remained the same even after storage for six months, both at room temperature and also at 40° C. (not shown). - The analysis from the differential scanning calorimetry also enabled predictions to be made about the solidification temperature of the PG(4)-C18 partial ester. The peak of the exothermic maximum upon cooling the sample down was between 53.4° C. and 57.0° C. with the maximum at 55.2° C., which marks the solidification temperature.
-
FIG. 10 shows a diagram illustrating the measurement of the contact angle (see para [0020]). For PG(4)-C18 partial esters, the contact angle is approximately 84°, which correlates to a HLB value of approximately 5.2. Compared with other polyglycerol fatty acid esters, PG(4)-C18 partial esters can be assigned to the hydrophilic polyglycerol fatty acid esters, as can be seen inFIG. 11 (here=PG4-C18).FIG. 12 shows the variation in contact angle for PG(4)-C18 partial esters, see central graph, against the start measurement (left hand column), after 16 weeks at room temperature (central column) and after 16 weeks at 40° C. (right hand column). The contact angle varied by no more than 10°, and so the hydrophobicity can be described as stable compared with monoglycerol fatty acid esters such as tristearyl glycerol, for example. This is also the case for the PG3-C16/C18 partial ester also shown inFIG. 12 , left hand graph, and PG6-C18 partial esters, right hand graph.
Claims (23)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEPCT/DE2018/000302 | 2018-10-22 | ||
PCT/DE2018/000302 WO2020083411A1 (en) | 2018-10-22 | 2018-10-22 | Coating material for use in an hmc method |
DEPCT/DE2018/000363 | 2018-12-11 | ||
PCT/DE2018/000363 WO2020119839A1 (en) | 2018-12-11 | 2018-12-11 | Process for preparing polyglycerol ester of fatty acids |
PCT/DE2019/000115 WO2020083412A1 (en) | 2018-10-22 | 2019-04-30 | Additive for a powder material intended for compaction into shaped bodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210361581A1 true US20210361581A1 (en) | 2021-11-25 |
Family
ID=66646996
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/278,674 Abandoned US20210361581A1 (en) | 2018-10-22 | 2019-04-30 | Additive for a powder material intended for compaction into shaped bodies |
US17/277,825 Active 2039-09-27 US12121613B2 (en) | 2018-10-22 | 2019-07-01 | Lipophilic transport particles for cosmetic or pharmaceutical active ingredients |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/277,825 Active 2039-09-27 US12121613B2 (en) | 2018-10-22 | 2019-07-01 | Lipophilic transport particles for cosmetic or pharmaceutical active ingredients |
Country Status (5)
Country | Link |
---|---|
US (2) | US20210361581A1 (en) |
EP (2) | EP3870229A1 (en) |
CN (2) | CN113242738B (en) |
BR (2) | BR112021006425A2 (en) |
WO (1) | WO2020083412A1 (en) |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6092213A (en) * | 1983-10-25 | 1985-05-23 | Riken Vitamin Co Ltd | Production of tablet and tablet confectionery |
JPS60105632A (en) * | 1983-11-15 | 1985-06-11 | Taiyo Kagaku Kk | Lubricant for tableting |
US4755387A (en) | 1985-03-21 | 1988-07-05 | The Procter & Gamble Company | Therapeutic particles |
NZ231281A (en) | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
TW209174B (en) | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
US5891476A (en) | 1997-12-22 | 1999-04-06 | Reo; Joe P. | Tastemasked pharmaceutical system |
US6117451A (en) * | 1998-08-25 | 2000-09-12 | Pharmalogix, Inc. | Direct compression metformin hydrochloride tablets |
CN1812793A (en) * | 2003-06-27 | 2006-08-02 | 大塚制药株式会社 | Sustained drug-relase particles and process for producing the same |
US8568779B2 (en) | 2007-01-11 | 2013-10-29 | Kaneka Corporation | Method for producing coenzyme Q10 particle |
IT1398648B1 (en) | 2010-03-09 | 2013-03-08 | Probiotical Spa | FOOD PRODUCT INCLUDING PROBIOTIC BACTERIA COATED WITH A VEGETABLE ORIGIN COATING. |
US9061352B2 (en) * | 2010-08-30 | 2015-06-23 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
WO2013183062A2 (en) * | 2012-06-05 | 2013-12-12 | Rubicon Research Private Limited | Palatable formulations of ibuprofen |
EP3641750A4 (en) * | 2017-06-20 | 2021-03-24 | Respirion Pharmaceuticals Pty Ltd | Method for reducing lung infection |
-
2019
- 2019-04-30 US US17/278,674 patent/US20210361581A1/en not_active Abandoned
- 2019-04-30 CN CN201980065505.7A patent/CN113242738B/en active Active
- 2019-04-30 EP EP19726304.9A patent/EP3870229A1/en active Pending
- 2019-04-30 WO PCT/DE2019/000115 patent/WO2020083412A1/en unknown
- 2019-04-30 BR BR112021006425-7A patent/BR112021006425A2/en unknown
- 2019-07-01 US US17/277,825 patent/US12121613B2/en active Active
- 2019-07-01 CN CN201980065571.4A patent/CN112867481A/en active Pending
- 2019-07-01 BR BR112021006416A patent/BR112021006416A2/en unknown
- 2019-07-01 EP EP19742277.7A patent/EP3870144A1/en active Pending
Non-Patent Citations (2)
Title |
---|
Tomar (Formulation and In Vitro Evaluation of Metformin Hydrochloride Direct Compressible Tablet using By HicelTM Microcrystalline Cellulose Excipient, World Journal of Pharmaceutical Research, Vol. 5, Issue 11, pp 1332-1344). (Year: 2016) * |
Uchimoto (A comparative study of glycerin fatty acid ester and magnesium stearate on the dissolution of acetaminophen tablets using the analysis of available surface area, European Journal of Pharmaceutics and Biopharmaceutics, Vol. 78, Issue 3, pp. 492-498). (Year: 2011) * |
Also Published As
Publication number | Publication date |
---|---|
BR112021006425A2 (en) | 2021-07-27 |
CN113242738B (en) | 2024-07-16 |
WO2020083412A1 (en) | 2020-04-30 |
US20210361577A1 (en) | 2021-11-25 |
BR112021006416A2 (en) | 2021-07-06 |
US12121613B2 (en) | 2024-10-22 |
CN113242738A (en) | 2021-08-10 |
CN112867481A (en) | 2021-05-28 |
EP3870144A1 (en) | 2021-09-01 |
EP3870229A1 (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2519679C2 (en) | Pharmaceutical dosed form, containing polymer carrier composition | |
ES2599031T3 (en) | Process for the preparation of an intermediate powder formulation and a final solid dosage form using a spray freezing step | |
US20230165799A1 (en) | Twin-screw dry granulation for producing solid formulations | |
Aoshima et al. | Glycerin fatty acid esters as a new lubricant of tablets | |
JPH0645564B2 (en) | Granular mannitol for direct compression processing and method for producing the same | |
US20210361581A1 (en) | Additive for a powder material intended for compaction into shaped bodies | |
JP5756749B2 (en) | Direct compressible and fast disintegrating tablet matrix | |
JP7376582B2 (en) | Additive for powder materials for compression into compacts | |
CN112703015B (en) | Coating material for use in HMC process | |
EP0941069A1 (en) | COMPACT MEMBER COMPRISING A PLURALITY OF POROUS CELLULOSE MATRICES, (PCMs), METHOD OF MANUFACTURING AND USE THEREOF | |
Chaiya et al. | Differential scanning calorimetric analysis for incompatibility: sodium stearate/magnesium stearate and acidic compounds | |
Peddapatla | A study of magnesium stearate behaviour in pharmaceutical blends and tablets employing Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS) | |
JP2022131609A (en) | Tablet and method for producing the same | |
Mohammed et al. | Diluent performance of a three component co-processed excipient for formulating ibuprofen tablets by wet granulation | |
Shinebaum | Investigating the mechanical properties of pharmaceutical excipients in granule and tablet production | |
Gejage et al. | Influence of Different Meltable Binders on the Solid-State Behaviour and Dissolution Profiles of Solid Lipid Extrudates Processed Via Continuous Hot Melt Granulation | |
PIOGLITAZONE | PHARMACEUTICAL SCIENCES | |
Nasser et al. | Enhancing Dissolution and Physicomechanical Properties of Indomethacin via Crystal Agglomeration Technique in Presence of Different Additives | |
Windbergs | Towards a better understanding of lipid-based matrices–Innovations in the production and analysis of physically stable solid lipid extrudates with tailor-made dissolution profiles | |
Urvashi | FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLET OF METOPROLOL SUCCINATE BY HOT MELT EXTRUSION TECHNIQUE | |
Bhoi et al. | Spherical Crystallization: Novel Technique | |
Van der Watt | Assessment of the characteristics of chitosan processed by spherical agglomeration |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IOI OLEO GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOCHMANN, DIRK;REYER, SEBASTIAN;SALAR BEHZADI, SHARAREH;AND OTHERS;SIGNING DATES FROM 20210303 TO 20210309;REEL/FRAME:055679/0472 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |